Physician
Radiation Oncology
Dr. Seth A. Rosenthal, MD
|
|
Give Review
Dr. Seth A. Rosenthal is an expert in the field of Radiation Oncology. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He has 1 awards "CMS Meaningful Use Stage 1 Certification". Seth Rosenthal is a published doctor and has 26 publications published. The lastest was: 'ACR Appropriateness Criteria Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer.'
Publications
- ACR Appropriateness Criteria® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer.
- Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.
- Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific...
- American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS).
- ACR Appropriateness Criteria Prostate Cancer-Pretreatment Detection, Staging, and Surveillance.
- American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Total Body Irradiation (TBI).
- On using 3D γ-analysis for IMRT and VMAT pretreatment plan QA.
- ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer.
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
- ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
- Liking is not the opposite of disliking: The functional separability of positive and negative attitudes toward minority groups.
- Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.
- American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy.
- ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer.
- Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 an...
- Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315.
- Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
- ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
- RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.
- Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
- Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and...
- Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate ...
- Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer.
- Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
Schools
Yale University School Of Medicine
Yale New Haven Hospital
University Of Pennsylvania
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Pennsylvania Health System -
Yale-New Haven Hospital -
Yale University School of Medicine
Hospital
-
Mercy General Hospital -
Mercy Hospital of Folsom -
Mercy San Juan Medical Center -
Sutter Auburn Faith Hospital -
Sutter Davis Hospital -
Sutter Medical Center, Sacramento -
Sutter Roseville Medical Center
Drug Facts
| NPI NUMBER | 1881690584 | |
| NPPES Provider LastName | ROSENTHAL | |
| NPPES Provider FirstName | SETH | |
| NPPES Provider ZIPCode | 958165120 | |
| NPPES Provider State | CA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 293.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881690584 |
| Last Name Of The Provider | ROSENTHAL |
| First Name Of The Provider | SETH |
| View All |
Similar Doctors
|
|
Dr. Brian J. Goldsmith, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janice Ryu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bihai Peng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Darryl C. Hunter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derrick G. Schmidt, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark D. Logsdon, MD
This Doctor is OpenDoctor Recommended.
|